drugset / Trial / NCT00183404

Long-Term Olanzapine Treatment in Children With Autism

NCT00183404

NaSingle-groupOpen-labelTreatment

Summary

This study will determine the short- and long-term safety and effectiveness of the drug olanzapine (Zyprexa®) for reducing symptoms of autism in children.

Timeline

Start
2004-09
Primary completion
2011-07
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Olanzapine Small molecule 2.5 mg
Subject Olanzapine Small molecule 20 mg

Indications